{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:40:25Z","timestamp":1788349225317,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1F31CA183547-01"],"award-info":[{"award-number":["1F31CA183547-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.critrevonc.2023.104081","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:34:27Z","timestamp":1690947267000},"page":"104081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Risk factors for developing both primary breast and primary ovarian cancer: A systematic review"],"prefix":"10.1016","volume":"190","author":[{"given":"Jennifer S.","family":"Ferris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ottman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine M.","family":"Genkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.104081_bib1","unstructured":"American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022\u20132024. Atlanta: American Cancer Society; 2022."},{"key":"10.1016\/j.critrevonc.2023.104081_bib2","unstructured":"American Cancer Society. Cancer Facts & Figures. 2023."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104081_bib3","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0959-8049(01)00282-9","article-title":"Breast cancer risk in women with a primary ovarian cancer--a case-control study","volume":"37","author":"Bergfeldt","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"9337","key":"10.1016\/j.critrevonc.2023.104081_bib4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(02)11023-3","article-title":"Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study","volume":"360","author":"Bergfeldt","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104081_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canep.2010.07.001","article-title":"Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer","volume":"35","author":"Berkowitz","year":"2011","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","article-title":"Second malignancies after breast cancer: the impact of different treatment modalities","volume":"98","author":"Kirova","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104081_bib7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.ejca.2005.01.029","article-title":"Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972-2001","author":"Soerjomataram","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104081_bib8","first-page":"1564","article-title":"Second malignant neoplasms among long-term survivors of ovarian cancer","volume":"56","author":"Travis","year":"1996","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/ijgc-00009577-200409000-00002","article-title":"Common risk factors of breast and ovarian cancer: recent view","volume":"14","author":"Zografos","year":"2004","journal-title":"Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.critrevonc.2023.104081_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer","volume":"472","author":"Permuth-Wey","year":"2009","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104081_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104081_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/bjc.2013.803","article-title":"Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry","volume":"110","author":"Ferris","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"9017","key":"10.1016\/j.critrevonc.2023.104081_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"347","author":"Breast cancer","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.104081_bib14","unstructured":"Wells G., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. \u3008http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\u3009. Accessed November 6, 2020."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104081_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104081_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijc.32259","article-title":"Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study","volume":"146","author":"Li","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104081_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12672-018-0330-0","article-title":"Risk of second primary female genital malignancies in women with breast cancer: a SEER analysis","volume":"9","author":"Li","year":"2018","journal-title":"Horm. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.ijrobp.2008.07.004","article-title":"Nonbreast second malignancies after treatment of primary breast cancer","volume":"73","author":"Yadav","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01807033","article-title":"Age at diagnosis and multiple primary cancers of the breast and ovary","volume":"41","author":"Suris-Swartz","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104081_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/bjc.2012.270","article-title":"Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer","volume":"107","author":"Kwast","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104081_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","article-title":"Breast cancer risk factors and second primary malignancies among women with breast cancer","volume":"105","author":"Trentham-Dietz","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00432-018-2621-9","article-title":"Multiple primary non-breast tumors in breast cancer survivors","volume":"144","author":"Corso","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104081_bib24","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0959-8049(01)00282-9","article-title":"Breast cancer risk in women with a primary ovarian cancer--a case-control study","volume":"37","author":"Bergfeldt","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2013.01.002","article-title":"Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG)","volume":"106","author":"Grantzau","year":"2013","journal-title":"Radiother. Oncol.: J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib26","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1016\/j.clbc.2018.04.009","article-title":"Inducing or preventing subsequent malignancies for breast cancer survivors? Double-edged sword of estrogen receptor and progesterone receptor","volume":"18","author":"Hu","year":"2018","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104081_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijrobp.2006.12.011","article-title":"Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review","volume":"68","author":"Kirova","year":"2007","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2001.tb01040.x","article-title":"Second primary cancers following breast cancer in the Japanese female population","volume":"92","author":"Tanaka","year":"2001","journal-title":"Jpn. J. Cancer Res.: Gann"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104081_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104081_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006117220284","article-title":"Tamoxifen and risk of large bowel cancer in women with breast cancer","volume":"53","author":"Newcomb","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104081_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/0284186X.2016.1273547","article-title":"Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen","volume":"56","author":"Rosell","year":"2017","journal-title":"Acta Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104081_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jnci\/87.9.645","article-title":"Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group","volume":"87","author":"Rutqvist","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0301-2115(00)00376-6","article-title":"Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study","volume":"95","author":"Ursic Vrscaj","year":"2001","journal-title":"Eur. J. Obstet. Gynecol., Reprod. Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104081_bib34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/oxfordjournals.annonc.a010406","article-title":"Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan","volume":"11","author":"Matsuyama","year":"2000","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104081_bib35","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jnci\/87.18.1359","article-title":"Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers","volume":"87","author":"Cook","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104081_bib36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/00000478-199506000-00012","article-title":"Follicular lymphoma adjacent to foreign body granulomatous inflammation and fibrosis surrounding silicone breast prosthesis","volume":"19","author":"Cook","year":"1995","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bjc.2016.108","article-title":"A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction","volume":"115","author":"Warschkow","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104081_bib38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/pin.12202","article-title":"Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype","volume":"64","author":"Senkus","year":"2014","journal-title":"Pathol. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2013.09.004","article-title":"Synchronous and metachronous metastatic breast cancer--two incarnations of the same beast?","volume":"23","author":"Senkus","year":"2014","journal-title":"Breast (Edinb., Scotl. )"},{"key":"10.1016\/j.critrevonc.2023.104081_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12609-013-0114-z","article-title":"Alcohol intake and breast cancer risk: weighing the overall evidence","volume":"5","author":"McDonald","year":"2013","journal-title":"Curr. Breast Cancer Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104081_bib41","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00394-020-02332-y","article-title":"Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis","volume":"60","author":"Khodavandi","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.critrevonc.2023.104081_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2020.01.002","article-title":"Racial\/ethnic disparities in ovarian cancer research","volume":"146","author":"Peres","year":"2020","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104081_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djj001","article-title":"Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations","volume":"98","author":"Travis","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104081_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41571-021-00491-3","article-title":"The ten genes for breast (and ovarian) cancer susceptibility","volume":"18","author":"Foulkes","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104081_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev.: Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104081_bib46","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:48:37Z","timestamp":1760903317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":46,"alternative-id":["S1040842823001695"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104081","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for developing both primary breast and primary ovarian cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104081"}}